Welcome to our dedicated page for Unitedhealth Gp SEC filings (Ticker: UNH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
UnitedHealth Group Incorporated (UNH) provides extensive disclosure to investors and regulators through its SEC filings, including annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K. These documents offer a detailed view of the company’s health care and well-being operations, which span UnitedHealthcare’s health benefit programs and Optum’s health services, technology and analytics businesses.
Annual and quarterly reports describe UnitedHealth Group’s consolidated financial condition and results of operations, as well as segment performance for UnitedHealthcare and Optum. They include information on revenues, earnings from operations, medical costs, operating costs, cash flows, capital structure and risk factors. Investors use these filings to understand how trends in medical utilization, Medicare and Medicaid funding, and pharmacy services affect the company’s financial profile.
Current reports on Form 8-K provide timely updates on material events. Recent 8-K filings have covered topics such as quarterly earnings releases, reaffirmation of earnings outlooks, amendments to bylaws to reflect changes in the company’s registered office and registered agent in Delaware, the appointment of new independent directors, and investor presentations. Some 8-K items are furnished under Regulation FD to share information discussed with investors and analysts, including earnings expectations and the impact of acquisitions like Amedisys.
UnitedHealth Group also files 8-Ks to document governance and leadership changes, including the appointment of directors with regulatory and clinical backgrounds. These filings often reference standard indemnification agreements and compensation arrangements for non-employee directors, providing additional transparency into board practices.
On this SEC filings page, users can review UnitedHealth Group’s regulatory disclosures in one place. Real-time updates from EDGAR ensure that new 10-K, 10-Q and 8-K filings, as well as any amendments, appear promptly. AI-powered summaries can help explain complex sections, highlight key metrics, and clarify the implications of items such as changes in outlook, medical cost trends or bylaw amendments. Investors can also monitor executive and director changes reported on Form 8-K and use the filings history to track how UnitedHealth Group’s strategy, capital management and risk profile evolve over time.
Wayne S. DeVeydt, Chief Financial Officer of UnitedHealth Group Inc. (UNH), reported a non-derivative acquisition on 09/23/2025 of 66.899 shares of common stock. The filing states these shares represent dividend equivalents paid on outstanding restricted stock units and were recorded at a $0 price because they are dividend-equivalent awards rather than open-market purchases. After the transaction, Mr. DeVeydt beneficially owned 10,591.899 shares. The filing notes the dividend equivalents are subject to the same vesting and forfeiture terms as the underlying restricted stock units.
Kristen L. Gil, a director of UnitedHealth Group Inc. (UNH), reported a non-derivative acquisition on 09/23/2025 consisting of 7 shares credited as dividend equivalents on vested deferred stock units; these dividend equivalents vested immediately and follow the same terms as the underlying units. After the transaction Ms. Gil is shown as beneficially owning 1,738 shares directly and 3,800 shares indirectly through a trust. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person on 09/25/2025.
UnitedHealth Group (UNH) insider filing: This Form 4 reports that Patrick H. Conway, Chief Executive Officer, Optum, received 64.683 shares of UnitedHealth common stock on 09/23/2025 at no cost as dividend equivalents credited on outstanding restricted stock units. The entry shows these dividend equivalents are subject to the same vesting terms as the underlying restricted stock units and will be forfeited if those units do not vest. Following the reported transaction, Mr. Conway is shown as beneficially owning 10,536.194 shares (direct ownership). The filing was signed by an attorney-in-fact on behalf of Mr. Conway on 09/25/2025. The Form contains no option exercises, sales, or cash purchases; it discloses a routine issuance tied to compensation arrangements.
UnitedHealth Group (UNH) insider filing shows a small, non-cash award and details of the reporting person's holdings. On 09/23/2025 the filing reports acquisition of 50 shares as dividend equivalents on vested deferred stock units, recorded at a $0 price because they represent vested awards rather than open-market purchases. The form shows the reporting person holds 427,895.942 shares directly, plus 349.7439 shares indirectly in a 401(k) and 681,875 shares indirectly in trusts. Explanatory notes state certain trust-to-direct and direct-to-trust transfers occurred on August 14, 2025 and were exempt from reporting under Rule 16a-13.
Paul R. Garcia, a director of UnitedHealth Group Inc. (UNH), reported an internal acquisition on 09/23/2025 consisting of 11 common stock units recorded as acquired at $0 as dividend equivalents on vested deferred stock units. The filing shows 2,761 shares beneficially owned directly after the transaction and additional indirect holdings of 2,146 shares via a revocable trust plus 45 and 55 shares via two other trusts. The dividend equivalents vested immediately and carry the same terms as the underlying deferred stock units.
Timothy P. Flynn, a director of UnitedHealth Group Inc. (UNH), reported a Section 16 transaction dated 09/23/2025. The filing shows 61 shares of Common Stock were acquired as dividend equivalents on vested deferred stock units, with a reported price of $0. Following the transaction, Mr. Flynn beneficially owned 9,538 shares directly and 6,033 shares indirectly through a trust. The form was signed by an attorney-in-fact on 09/25/2025. The filing is a single-person Form 4 and lists Mr. Flynn's relationship to the issuer as a director.
Michele J. Hooper, a director of UnitedHealth Group (UNH), received 236 shares on 09/23/2025 as dividend equivalents tied to vested deferred stock units; the reporting indicates these dividend equivalents are immediately vested and carry the same terms as the underlying deferred stock units. After the transaction, Hooper beneficially owned 40,715 shares. The Form 4 was signed by an attorney-in-fact on 09/25/2025. No cash consideration was paid for the 236 shares, consistent with dividend-equivalent treatment.
Frederick W. McNabb III, a director of UnitedHealth Group Inc. (UNH), reported a transaction on Form 4 showing the acquisition of 49 shares of Common Stock on 09/23/2025 at no cash price. The filing explains these 49 shares represent dividend equivalents paid on vested deferred stock units, which are immediately vested and subject to the same terms as the underlying units. Following the transaction, Mr. McNabb beneficially owns 14,052 shares. The Form 4 was signed by an attorney-in-fact on 09/25/2025.
UnitedHealth Group (UNH) reporting person Charles D. Baker received 1,256 shares of common stock as dividend equivalents on vested deferred stock units. The shares were issued through an acquisition transaction coded A (dividend equivalents) on 09/23/2025 at no cash price ($0), and the ownership is held directly. The filing notes these dividend equivalents become immediately vested and carry the same terms as the underlying deferred stock units. The Form 4 was submitted by an attorney-in-fact on behalf of the reporting person.
John H. Noseworthy, M.D., a director of UnitedHealth Group Inc. (UNH), reported a non‑derivative acquisition on 09/23/2025. The filing shows 39 shares of Common Stock were acquired at a reported price of $0, described as dividend equivalents paid on vested deferred stock units that are immediately vested and subject to the same terms as the underlying deferred stock units. After the transaction, Dr. Noseworthy beneficially owned 6,432 shares of UNH. The Form 4 was signed by an attorney‑in‑fact on 09/25/2025.
FAQ
What is the current stock price of Unitedhealth Gp (UNH)?
What is the market cap of Unitedhealth Gp (UNH)?
